Immunovant, Inc. (IMVT) has a negative trailing P/E of -9.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 80.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -10.16%, forward earnings yield 1.24%.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -0.7 | 0.00 | -66.47 | 0.00 | - |
| 2019 | -319,266.2 | 3,192.67 | 5,825.65 | 0.00 | - |
| 2020 | -10.1 | 0.00 | 7.15 | 0.00 | - |
| 2021 | -13.1 | 0.63 | 3.60 | 0.00 | - |
| 2022 | -3.9 | -0.22 | 1.29 | 0.00 | - |
| 2023 | -9.0 | -0.46 | 5.27 | 0.00 | - |
| 2024 | -16.8 | -1.69 | 7.07 | 0.00 | - |
| 2025 | -6.3 | -0.14 | 3.66 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-13.67 | $0.00 | $-136.74M | - |
| 2019 | $0.00 | $0.00 | $-448.00 | - |
| 2020 | $-1.54 | $0.00 | $-66.39M | - |
| 2021 | $-1.22 | $0.00 | $-107.43M | - |
| 2022 | $-1.43 | $0.00 | $-156.73M | - |
| 2023 | $-1.71 | $0.00 | $-210.96M | - |
| 2024 | $-1.88 | $0.00 | $-259.34M | - |
| 2025 | $-2.73 | $0.00 | $-413.84M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.63 | $-2.87 – $-2.51 | $10.49M | $10.49M – $10.49M | 11 |
| 2027 | $-2.57 | $-3.02 – $-2.18 | $6.64M | $6.64M – $6.64M | 10 |
| 2028 | $-2.46 | $-3.69 – $-1.42 | $107.51M | $107.51M – $107.51M | 13 |
| 2029 | $-1.37 | $-2.47 – $0.13 | $460.43M | $460.43M – $460.43M | 8 |
| 2030 | $2.09 | $2.09 – $2.09 | $1.25B | $1.25B – $1.25B | 3 |
